Neoantigen-7-HLA-Binding-Novel-Peptides

Neoantigens are peptides derived from tumor-specific mutations, which are recognized by the immune system as foreign and can stimulate an immune response against cancer cells. Identifying these neoantigens is a crucial step in the development of personalized cancer immunotherapies, as they serve as targets for T-cell mediated immune responses. However, predicting which peptides from the tumor genome will bind effectively to major histocompatibility complex (MHC) molecules—key proteins that present antigens to immune cells—remains a significant challenge.

This tutorial outlines a comprehensive workflow for the identification, prediction, and validation of potential neoantigens. We begin by using the Immune Epitope Database (IEDB) to predict the binding affinity of peptide sequences to MHC molecules. IEDB provides powerful tools to model how peptides interact with different MHC alleles, helping to prioritize peptides that are most likely to be presented by the immune system. Next, we validate these peptides using PepQuery, a tool that allows for the comparison of predicted neoantigens with experimental proteomics data, providing an additional layer of confidence in their relevance. Finally, we categorize the peptides into strong and weak binders, based on their predicted affinity, which helps in identifying the most promising candidates for cancer immunotherapy.

新抗原（Neoantigens）是源自肿瘤特异性突变的肽段，可被免疫系统识别为非己物质，并能触发针对癌细胞的免疫应答。识别此类新抗原是个性化癌症免疫治疗开发的关键环节，因为它们可作为T细胞介导免疫应答的靶标。然而，预测肿瘤基因组中的哪些肽段能有效结合主要组织相容性复合体（MHC）——一类负责向免疫细胞呈递抗原的关键蛋白——仍是一项重大挑战。

本教程详述了一套用于潜在新抗原识别、预测与验证的完整流程。首先，我们将借助免疫表位数据库（IEDB）预测肽段序列与MHC分子的结合亲和力。IEDB提供了强大的工具，可用于模拟肽段与不同MHC等位基因的相互作用，助力优先筛选出最有可能被免疫系统呈递的肽段。随后，我们将使用PepQuery工具对上述肽段进行验证：该工具可将预测得到的新抗原与实验蛋白质组学数据进行比对，为其相关性提供额外的可信度支撑。最后，我们将根据预测的亲和力将肽段分为强结合肽与弱结合肽，从而助力筛选出癌症免疫治疗中最具潜力的候选靶点。